Biomarkers are a surrogate for clinical response.
Inflammation causes surges in CRP, ferritin, WCC, etc.
But serologic biomarker levels can be altered in the absence of a clinical response. So they will never be superior to a clinical endpoint.
For example, creatinine is used as a marker of renal function. When someone's kidneys are struggling creatinine increases.
But if someone's on trimethoprim for an infection, it competes with the excretion of creatinine and raises the level in the absence of renal impairment.
So, theoretically, if someone takes an immune-modulating therapy that decreases CRP production (or increases its excretion) but doesn't actually dampen inflammation, CRP would not be a relevant endpoint. Clinical response would be the key in that case.
- Forums
- ASX - By Stock
- Competition - Citius Novellus License Deal
Biomarkers are a surrogate for clinical response.Inflammation...
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.07 |
Change
0.005(0.47%) |
Mkt cap ! $1.216B |
Open | High | Low | Value | Volume |
$1.08 | $1.10 | $1.06 | $3.371M | 3.135M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 45345 | $1.06 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.07 | 3875 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 45345 | 1.055 |
9 | 193430 | 1.050 |
3 | 44331 | 1.045 |
5 | 117942 | 1.040 |
3 | 53830 | 1.035 |
Price($) | Vol. | No. |
---|---|---|
1.065 | 3875 | 2 |
1.070 | 28953 | 3 |
1.075 | 46564 | 3 |
1.080 | 87551 | 5 |
1.085 | 47614 | 4 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |